VeraDermics raises $472M in post-IPO equity after hair-loss drug IPO soars 567%
What's the deal? VeraDermics, a clinical-stage biotech developing an oral treatment for pattern hair loss (PHL), has raised $472 million in a post-IPO equity round, announced in May 2026. The company went public in February 2026 in what has become one of the year's standout debuts.
Why now? VeraDermics wanted to list before its Phase 3 clinical trial data landed. It raised a $150 million Series C in October 2025 to, in chief financial officer Dominic Carrano's words, "build capital" and attract "strong investors that could support us on a potential public entrance." Then it "ran toward the IPO window."
By the numbers: Shares more than doubled on the February 4 debut and were up 567% as of October 14 — the highest percentage return of any 2026 IPO, according to Renaissance CapitalDealroom has a profile for this one. Try Dealroom →, ahead of larger offerings from SpaceXDealroom has a profile for this one. Try Dealroom → and Cerebras Systems. At $472 million, the raise ranks in the 97th percentile of all US health post-IPO equity rounds on record.
What's the endgame? VeraDermics has one drug candidate, VDPHL01, an oral, non-hormonal extended-release formulation of minoxidil. It released Phase 2 results for women in August and expects topline Phase 3 data for men later this year. "VDPHL01 could be the first oral minoxidil approved for hair loss for both males and females," LeerinkDealroom has a profile for this one. Try Dealroom → analysts wrote.
The market is sizeable. VeraDermics estimates about 80 million people in the US — 50 million men and 30 million women — suffer from PHL.
The money picture: The company is not yet profitable. Second-quarter losses widened to $23.5 million, up from $15.6 million a year earlier, underscoring the cash demands of pushing a single candidate through late-stage trials.
What could go wrong? Everything hinges on one drug. VeraDermics listed before its pivotal Phase 3 men's data, so a disappointing readout — the last stage before seeking FDA approval — would hit a company whose valuation already rests on investor enthusiasm rather than revenue.
The signal: VeraDermics completed its IPO in roughly four months despite two government shutdowns that stalled SEC reviews, then tapped public markets again for $472 million. The run shows that even in a cautious window, a focused clinical-stage biotech with a large addressable market and strong aftermarket momentum can still raise heavily.
Read more: cfobrew.com
Image credit: Ivan Radic
